SBFM logo

SBFMSunshine Biopharma Inc

$2.11
$0.14
(6.14%)
Today
Closed $2.14
$0.03
(1.40%)
After Hours
Updated: 06:29 PM EDT
Mkt Cap$4.84M
Vol190,650.00
News
all
press releases
Why Sunshine Biopharma (SBFM) Stock Dropped After Hours Today
Sunshine Biopharma stock fell after hours after the company announced a 1-for-10 reverse stock split to maintain Nasdaq listing compliance.read more...
Benzinga
News Placeholder
More News
News Placeholder
Innovation Igniting into High-Growth Spotlight
As capital continues flowing into high-growth sectors tied to artificial intelligence, biotechnology, diagnostics, and defense technology, several emerging companies are rapidly capturing investor attention through financings, acquisitions, regulatory approvals, and platform expansion strategies. $SBFM, $TGNT, $CODX, $JUNS, $VIDA, $QUCY, $GFS, $GOOG, $MSFT, $NVDA
24-7 Market News
News Placeholder
Sunshine Biopharma Stock Rallies On Canadian Approval For Generic Amoxicillin
Sunshine Biopharma (NASDAQ: SBFM) shares are trading higher Thursday after securing Canadian regulatory approval for generic amoxicillin.read more...
Benzinga
News Placeholder
Why Is Sunshine Biopharma Stock Falling Tuesday?
SBFM stock plummets 18% in premarket trading after Sunshine Biopharma prices a $6M public offering at $0.50 per unit. Get the details.read more...
Benzinga
News Placeholder
Nasdaq Down 200 Points; Brady Earnings Top Views
US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs...
Benzinga
News Placeholder
Sunshine Biopharma Stock Powers Ahead Following Launch Of Generic Cholesterol-Lowering Drug By Canadian Unit
The drug, called Pravastatin, is a statin medication that works by lowering bad cholesterol (LDL) and increasing good cholesterol (HDL) in the blood, thereby helping prevent heart attacks, strokes, and other serious cardiovascular conditions.
Stocktwits
News Placeholder
Sunshine Biopharma Stock Soars After Launch Of First Biosimilar In $10B Canadian Market: Retail Bulls Charge In
The company launched Niopeg, a biosimilar to Neulasta, designed to reduce the risk of infection in chemotherapy patients.
Stocktwits
News Placeholder
Sunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’
CEO Steve Slilaty stated that the company is aiming to strengthen its presence in Canada’s generic drugs market, valued at $9.4 billion.
Stocktwits
News Placeholder
Sunshine Biopharma Boosts Retail Trader Appeal After Canadian Launch Of Generic Cancer Drug
Its subsidiary launched Everolimus — a generic version of Novartis’ Afinitor — in the Canadian generic prescription drug market.
Stocktwits
<
...
1
>

Advertisement|Remove ads.